Company Profile - Spero Therapeutics Inc

Introduction

Spero Therapeutics Inc. (Spero) is a clinical-stage biopharmaceutical company. It is engaged in developing, identifying and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections. Its product pipeline includes SPR994 oral gram-negative program, SPR741and SPR206 IV potentiator platform, and SPR720 non-tuberculosis mycobacterium. The company markets its products through third party distributors. Its partners include U.S. National Institute of Allergy and Infectious Diseases (NIAID), U.S. Department of Defense (DoD) and Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Spero is headquartered in Cambridge, Massachusetts, the US.